胶质母细胞瘤
免疫疗法
临床试验
医学
免疫系统
树突状细胞
抗原
肽疫苗
胶质瘤
脑瘤
肿瘤相关抗原
肿瘤微环境
免疫学
癌症研究
内科学
病理
表位
作者
Kelly Hotchkiss,Kristen A. Batich,Aditya Mohan,Rifaquat Rahman,Steven Piantadosi,Mustafa Khasraw
出处
期刊:Neuro-oncology
[Oxford University Press]
日期:2023-06-08
卷期号:25 (10): 1752-1762
被引量:3
标识
DOI:10.1093/neuonc/noad088
摘要
Glioblastoma is a deadly brain tumor without any significantly successful treatments to date. Tumor antigen-targeted immunotherapy platforms including peptide and dendritic cell (DC) vaccines, have extended survival in hematologic malignancies. The relatively "cold" tumor immune microenvironment and heterogenous nature of glioblastoma have proven to be major limitations to translational application and efficacy of DC vaccines. Furthermore, many DC vaccine trials in glioblastoma are difficult to interpret due to a lack of contemporaneous controls, absence of any control comparison, or inconsistent patient populations. Here we review glioblastoma immunobiology aspects that are relevant to DC vaccines, review the clinical experience with DC vaccines targeting glioblastoma, discuss challenges in clinical trial design, and summarize conclusions and directions for future research for the development of effective DC vaccines for patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI